Systemic inflammatory response syndrome and adverse outcomes in acute intracerebral hemorrhage: a meta-analysis.

Neurol SciOct 5, 2026 (epub)
Clinical ResearchNeurologyEmergency MedicineOpen access

Lang Bu, Honghua Dai, Hao Du et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis evaluated the prognostic significance of systemic inflammatory response syndrome (SIRS) in 6,976 patients with acute intracerebral hemorrhage (ICH). It found that SIRS significantly increased the risk of short-term mortality (OR 2.43) and poor functional outcomes at 3 and 12 months (OR 1.47 and OR 1.76, respectively), as well as hematoma expansion (OR 2.76).

Key findings

  • Patients with acute ICH and SIRS had a 2.43-fold higher risk of short-term mortality.
  • SIRS was associated with a 1.47-fold increased risk of poor functional outcome at 3 months.
  • At 12 months, the risk of poor functional outcome was 1.76 times higher in patients with SIRS.
  • SIRS increased the risk of hematoma expansion by 2.76 times.

Why it matters

Understanding the impact of SIRS on outcomes in acute ICH patients can help clinicians identify high-risk individuals and potentially guide management strategies to improve prognosis.

Source

PubMed · PMID 42830311Free full text on PubMed Central

Published in Neurol Sci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.